Multiple Myeloma News & Features
The 18-month progression-free survival rate was 71.6% among patients treated with daratumumab plus VMP compared with 50.2% among patients treated with VMP alone.
A study presented at the 2018 ASCO Annual Meeting investigated the mortality risk for patients with multiple myeloma who develop VTE.
Investigators sought to determine the impact on quality of life for patients with relapsed/refractory multiple myeloma treated with PAN and BTZ+DEX.
In a single-arm phase 2 study, researchers explored the effectiveness of a modified lenalidomide, bortezomib, and dexamethasone (RVD-lite) regimen in transplant-ineligible patients with multiple myeloma.
In this phase 2 study, 38 patients with previously untreated multiple myeloma who were ineligible for autologous stem cell transplantation were treated with a bortezomib-containing induction regimen until plateau.
Multiple Myeloma Clinical Trials
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|